Quantifying the Renal Impact of [ <sup>177</sup> Lu]Lu-PSMA-617: A Longitudinal Analysis of Real-World Data from the LUMEN Registry
Lu]Lu-PSMA-617 is associated with a slight long-term average decline in eGFR. Although this is unlikely to be clinically relevant for late-stage mCRPC, the cumulative dose effect warrants careful monitoring in earlier disease stages.
Authors
- Philipp Krausewitz (ORCID: https://orcid.org/0000-0002-8213-9975)
- Markus Essler
- Thomas Büttner (ORCID: https://orcid.org/0000-0003-0316-9621)
- Jim Küppers
- Milka Marinova (ORCID: https://orcid.org/0000-0002-1856-5005)
- Barbara Kreppel
- Leander Fritzsche
- Christian Hoffmann
- Florian Gärtner
- Manuel Ritter
Institutions
- University Hospital Bonn (DE)
Publication Details
- Journal
- Journal of Nuclear Medicine
- Published
- 2026-04-30
- DOI
- https://doi.org/10.2967/jnumed.125.271077
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00